ASKA Pharmaceutical Holdings Co (TSE:4886) EBIT per Share: 円251.79 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4886 ASKA Pharmaceutical Holdings Co Ltd TSE:4886
61 GF Score
Price 円2,244.00
GF Value 円2,402.15
Valuation Fairly Valued
View Full Analysis

What is ASKA Pharmaceutical Holdings Co EBIT per Share?

ASKA Pharmaceutical Holdings Co TSE:4886 +1.40% 61 EBIT per Share is 円251.79 as of Mar. 2026. GuruFocus rates TSE:4886 with a GF Score™ of 61/100 and a GF Value™ of 円2,402.15 (Fairly Valued). Among 813 Drug Manufacturers companies, ASKA Pharmaceutical Holdings Co ranks worse than 55.6% on this metric.

ASKA Pharmaceutical Holdings Co's EBIT per Share for the three months ended in Mar. 2026 was 円74.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円251.79.

During the past 12 months, the average EBIT per Share Growth Rate of ASKA Pharmaceutical Holdings Co was 9.30% per year. During the past 3 years, the average EBIT per Share Growth Rate was 4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for ASKA Pharmaceutical Holdings Co's EBIT per Share or its related term are showing as below:

TSE:4886' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 4.4   Med: 5.15   Max: 5.9
Current: 4.4

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of ASKA Pharmaceutical Holdings Co was 5.90% per year. The lowest was 4.40% per year. And the median was 5.15% per year.

TSE:4886's 3-Year EBIT Growth Rate is ranked worse than
55.6% of 813 companies
in the Drug Manufacturers industry
Industry Median: 7.5 vs TSE:4886: 4.40

ASKA Pharmaceutical Holdings Co's EBIT for the three months ended in Mar. 2026 was 円2,101 Mil.

ASKA Pharmaceutical Holdings Co  (TSE:4886) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

ASKA Pharmaceutical Holdings Co EBIT per Share Related Terms

ASKA Pharmaceutical Holdings Co EBIT per Share Historical Data

* Premium members only.

The historical data trend for ASKA Pharmaceutical Holdings Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ASKA Pharmaceutical Holdings Co EBIT per Share Chart

ASKA Pharmaceutical Holdings Co Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT per Share
205.63 191.47 349.73 220.24 254.16

ASKA Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.88 62.33 38.70 76.73 74.03
TSE:4886
61GF Score
ASKA Pharmaceutical Holdings Co Ltd TSE:4886
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ASKA Pharmaceutical Holdings Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

ASKA Pharmaceutical Holdings Co's EBIT per Share for the fiscal year that ended in Mar. 2026 is calculated as

EBIT per Share(A: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=7213/28.380
=254.16

ASKA Pharmaceutical Holdings Co's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=2101/28.380
=74.03

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円251.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of 円251.79 mean?
ASKA Pharmaceutical Holdings Co (TSE:4886) has a EBIT per Share of 円251.79 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. According to the industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #452 out of 813 companies in the Drug Manufacturers industry, placing it in the top 55.6%.
Is ASKA Pharmaceutical Holdings Co's EBIT per Share too high?
ASKA Pharmaceutical Holdings Co's current EBIT per Share is 円251.79. Based on the distribution chart, ASKA Pharmaceutical Holdings Co ranks #452 out of 813 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ASKA Pharmaceutical Holdings Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ASKA Pharmaceutical Holdings Co's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #452 out of 813 companies for EBIT per Share. This places ASKA Pharmaceutical Holdings Co in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ASKA Pharmaceutical Holdings Co's current EBIT per Share is 円251.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASKA Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co (TSE:4886) is currently considered Fairly Valued. The stock's GF Value™ is 円2,402.15, compared to a current price of 円2,244.00 — trading 6.6% below its estimated fair value. The current EBIT per Share is 円251.79. ASKA Pharmaceutical Holdings Co's overall GF Score™ is 61/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For ASKA Pharmaceutical Holdings Co (TSE:4886), the current EBIT per Share is 円251.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ASKA Pharmaceutical Holdings Co (TSE:4886) Overvalued in 2026?

Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of 円2,244.00 is trading 6.6% below its estimated GF Value™ of 円2,402.15. GuruFocus considers ASKA Pharmaceutical Holdings Co to be Fairly Valued.

Key valuation signals for TSE:4886:

  • EBIT per Share: 円251.79
  • GF Value™: 円2,402.15 vs. price of 円2,244.00 (6.6% below fair value)
  • GF Score™: 61/100

No single metric tells the full story. See the TSE:4886 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ASKA Pharmaceutical Holdings Co Business Description

Address 2-5-1 Shibaura, Minato-ku, Tokyo, JPN, 108-8532
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and other related operations.
61GF Score

Get the complete analysis for TSE:4886

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,244.00
Price
円2,402.15
GF Value